Skip to main content
Equibles
AGEN logo

AGEN · Agenus Inc · Earnings Call Transcripts & Audio

Track AGEN — free

Use AGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.93 +0.04 (+0.40%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 7, 2026
Market Cap
$427.47M
Shares
45.02M
Volume · Sep 30 1.37M Avg daily vol (3M) 4.21M

Agenus Inc Earnings Call Transcripts

Quarterly earnings calls for Agenus Inc (AGEN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲95% $20.93M −$49.23M '22 Q2 22-08-09 ▼91% $22.77M −$56.72M '22 Q3 22-11-08 ▲40.1% $28.39M −$74.10M '22 Q4 23-03-14 ▼11.7% $22.90M −$70.89M '23 Q1 23-05-09 ▲6.8% $24.31M −$64.53M '23 Q3 23-11-07 ▲195.2% $83.80M −$48.58M '23 Q4 24-03-14 ▲22.3% $28.00M −$63.45M '24 Q1 24-05-07 ▼7.1% $23.51M −$54.80M '24 Q2 24-08-08 ▲3.3% $25.11M −$67.21M '24 Q3 24-11-12 ▼68% $26.84M −$46.81M '24 Q4 25-03-11 ▼14.1% $24.07M −$26.37M '25 Q1 25-05-12 ▲9.3% $25.69M −$30.01M '25 Q2 25-08-27 ▲20.4% $30.23M $63.91M '25 Q3 25-12-03 ▲27.5% $34.20M −$10.61M '25 Q4 26-03-31 ▲40.2% $33.74M $39.21M '26 Q1 26-05-11 LATEST ▲34.4% $34.52M −$567,000 '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Agenus Inc (AGEN) Q2 2026 Earnings Call
Revenue
$34.52M
▲ 34.4% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Agenus Inc (AGEN) Q1 2026 Earnings Call
Revenue
$33.74M
▲ 40.2% YoY
Diluted EPS
$1.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
Agenus Inc (AGEN) Q4 2025 Earnings Call
Revenue
$34.20M*
▲ 27.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-12-03
Agenus Inc (AGEN) Q3 2025 Earnings Call
Revenue
$30.23M
▲ 20.4% YoY
Diluted EPS
$1.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-27
Agenus Inc (AGEN) Q2 2025 Earnings Call Transcript
Confident tone BOT/BAL immunotherapy efficacy in colorectal cancer Regulatory challenges and FDA delays Phase III trial with CCTG
Revenue
$25.69M
▲ 9.3% YoY
Diluted EPS
$-1.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Agenus Inc (AGEN) Q1 2025 Earnings Call Transcript
Confident tone BOT/BAL clinical data FDA and regulatory environment Colorectal cancer unmet need
Revenue
$24.07M
▼ 14.1% YoY
Diluted EPS
$-1.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Agenus Inc (AGEN) Q4 2024 Earnings Call Transcript
Confident tone BOT/BAL clinical activity in colorectal cancer Organ-sparing potential (rectal/colon cancer) Non-core asset monetization
Revenue
$26.84M*
▼ 68% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Agenus Inc (AGEN) Q3 2024 Earnings Call Transcript
Positive tone BOT/BAL clinical data in MSS colorectal cancer Upcoming data presentations and pipeline readouts Phase 3 design and regulatory feedback
Revenue
$25.11M
▲ 3.3% YoY
Diluted EPS
$-3.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Agenus Inc (AGEN) Q2 2024 Earnings Call Transcript
Confident tone BOT/BAL in colorectal cancer FDA regulatory interaction and accelerated filing Phase II data and upcoming November dataset
Revenue
$23.51M
▼ 7.1% YoY
Diluted EPS
$-2.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript
Positive tone BOT/BAL lead program in colorectal cancer Pipeline expansion across other tumors Regulatory pathway and FDA alignment
Revenue
$28.00M
▲ 22.3% YoY
Diluted EPS
$-3.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Agenus Inc (AGEN) Q4 2023 Earnings Call Transcript
Confident tone Regulatory pathway and FDA BOT/BAL program and data Phase 2 trial readout timing
Revenue
$83.80M*
▲ 195.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Agenus Inc (AGEN) Q3 2023 Earnings Call Transcript
Revenue
$24.31M
▲ 6.8% YoY
Diluted EPS
$-3.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Agenus Inc (AGEN) Q1 2023 Earnings Call Transcript
Revenue
$22.90M
▼ 11.7% YoY
Diluted EPS
$-4.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-14
Agenus Inc (AGEN) Q4 2022 Earnings Call Transcript
Revenue
$28.39M*
▲ 40.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Agenus Inc (AGEN) Q3 2022 Earnings Call Transcript
Revenue
$22.77M
▼ 91% YoY
Diluted EPS
$-3.80
▼ 126.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Agenus Inc (AGEN) Q2 2022 Earnings Call Transcript
Revenue
$20.93M
▲ 95% YoY
Diluted EPS
$-3.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-06-29
Agenus Inc (AGEN) Q1 2022 Earnings Call Transcript
Revenue
$25.94M
▲ 121.4% YoY
Diluted EPS
$-3.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Agenus Inc (AGEN) Q4 2021 Earnings Call Transcript
Revenue
$20.26M*
▼ 35.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Agenus Inc (AGEN) Q3 2021 Earnings Call Transcript
Revenue
$252.95M
▲ 1605.5% YoY
Diluted EPS
$14.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Agenus Inc (AGEN) Q2 2021 Earnings Call Transcript
Revenue
$10.73M
▼ 60.2% YoY
Diluted EPS
$-7.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Agenus Inc (AGEN) Q1 2021 Earnings Call Transcript
Revenue
$11.72M
▼ 22.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-15
Agenus Inc (AGEN) Q4 2020 Earnings Call Transcript
Revenue
$31.27M
▼ 9.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-16
Agenus Inc (AGEN) Q3 2020 Earnings Call Transcript
Revenue
$14.83M
▼ 25.6% YoY
Diluted EPS
$-5.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Agenus Inc (AGEN) Q2 2020 Earnings Call Transcript
Revenue
$26.95M
▲ 71.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Agenus Inc (AGEN) Q1 2020 Earnings Call Transcript
Revenue
$15.13M
▼ 81.1% YoY
Diluted EPS
$-6.08
▼ 358.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Agenus Inc (AGEN) Q4 2019 Earnings Call
Revenue
$34.50M
▲ 434.8% YoY
Diluted EPS
$-4.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 earnings calls
Key facts CIK 1098972 CUSIP 00847G804 13F (30d) 2 filings 2 filers Visit website Investor relations